



**Sou o paciente: qual abordagem
cirúrgica devo escolher: prostatectomia
aberta vs. robótica - **Aberta****

Alvaro S. Sarkis
Professor Livre Docente
Universidade de São Paulo
ICESP

“INTUITIVE” MARKET VALUE = \$24.3 Billion

X

UROLOGIST MARKET VALUE =?



Indications of ORRP vs RALRP

As mesmas


Robotic surgery evaluation: 10 years

- 2003–2013, the number of RARP increased from about 1.8% to 85% in the USA
- despite the lack of high level evidence comparing robotic surgery to the standard, cheaper, open technique


Prostatectomia aberta versus robótica

Qual a melhor técnica?


EXISTE RESPOSTA???




ÁLVARO 2018?



ÁLVARO 2002 - 2007



Denonvilliers' fascia





J. Garcia
© 2003
Brady Urological
Institute

Copyright © 2003 Brady Urological Institute


Incisão








Dissecção do colo vesical



Dissecção do colo vesical



Meta-analysis

EUROPEAN UROLOGY 62 (2012) 1–15

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



Platinum Priority – Review – Prostate Cancer

Editorial by Quoc-Dien Trinh, Khurshid R. Ghani and Mani Menon on pp. 16–18 of this issue

Positive Surgical Margin and Perioperative Complication Rates of Primary Surgical Treatments for Prostate Cancer: A Systematic Review and Meta-Analysis Comparing Retropubic, Laparoscopic, and Robotic Prostatectomy

Ashutosh Tewari^{a,*}, Prasanna Sooriakumaran^{a,b}, Daniel A. Bloch^c, Usha Seshadri-Kreaden^d, April E. Hebert^d, Peter Wiklund^b


^aInstitute of Prostate Cancer and LeFrak Center for Robotic Surgery, James Buchanan Brady Foundation Department of Urology, Weill Cornell Medical College–New York Presbyterian Hospital, New York, NY, USA; ^bDepartment of Molecular Medicine and Surgery, Karolinska University Hospital, Solna, Sweden; ^cDepartment of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA; ^dDepartment of Clinical Affairs, Intuitive Surgical Inc., Sunnyvale, CA, USA

167,184 Open
62,389 Robotic

Perda de sangue

Blood loss

Blood loss




159/700ml


Perioperative outcomes	Weighted average						Propensity-adjusted estimates					
	Unadjusted estimates			Unadjusted p values			Adjusted differences ^a			Adjusted p value		
	ORP	LRP	RALP	ORP vs LRP	ORP vs RALP	LRP vs RALP	ORP minus LRP	ORP minus RALP	LRP minus RALP	ORP vs LRP	ORP vs RALP	LRP vs RALP
Estimated blood loss, ml												
Cohorts (patients), n	94 (31 492)	80 (24 688)	112 (41 672)									
Mean (SD)	745.3 (396.0)	377.5 (206.8)	188.0 (86.5)	<0.0001*	<0.0001*	<0.0001*	363.1	562.5	127.8	<0.0001*	<0.0001*	<0.0001*
95% CI	665.4-825.6	332.2-423.0	174.1-204.5				272.4-453.8	485.2-639.8	95.4-160.2			

Complication Rates

Intra-operative complication rates



Perioperative complication rates



Primary outcome	Unadjusted estimates						Propensity-adjusted estimates					
	Weighted averages			Unadjusted p value			Adjusted differences ^a			Adjusted p value		
	ORP	LRP	RALP	ORP vs LRP	ORP vs RALP	LRP vs RALP	ORP minus LRP	ORP minus RALP	LRP minus RALP	ORP vs LRP	ORP vs RALP	LRP vs RALP
Total intraoperative												
Cohorts (patients), n	39 (16 647)	57 (16 389)	42 (14 309)	0.79	0.0005*	<0.0001*	-0.32	1.15	1.10	0.93	<0.0001*	<0.0001*
Mean (SD)	1.5 (1.6)	1.6 (1.9)	0.4 (0.5)				-1.0 to 0.4	0.7-1.6	0.7-1.5			
95% CI	1.0-2.0	1.1-2.1	0.4-0.7									
Total perioperative												
Cohorts (patients), n	39 (16 647)	57 (16 389)	42 (14 309)	0.0008*	<0.0001*	0.04*	5.24	13.76	6.74	0.08	<0.0001*	0.002*
Mean (SD)	17.9 (9.1)	11.1 (9.6)	7.8 (6.3)				-0.7 to 11.1	9.5-18.0	2.6-10.9			
95% CI	15.0-20.8	8.6-13.6	5.9-9.7									

Eur Urol. 2012 Jul;62(1):1-15. doi: 10.1016/j.eururo.2012.02.029. Epub 2012 Feb 24.
 Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy.
 Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreiden U, Hebert AE, Wiklund P.

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



Platinum Priority – Review – Prostate Cancer

Editorial by Quoc-Dien Trinh, Khurshid R. Ghossein and Mani Menon on pp. 16–18 of this issue

Positive Surgical Margin and Perioperative Complication Rates of Primary Surgical Treatments for Prostate Cancer: A Systematic Review and Meta-Analysis Comparing Retropubic, Laparoscopic, and Robotic Prostatectomy

Ashutosh Tewari^{a,*}, Prasanna Sooriakumaran^{a,b}, Daniel A. Bloch^c, Usha Seshadri-Kreaden^d,
April E. Hebert^d, Peter Wiklund^b

^dDepartment of Clinical Affairs, Intuitive Surgical Inc., Sunnyvale, CA, USA

available at www.sciencedirect.comjournal homepage: www.europeanurology.com

European Association of Urology



■ Robotic

■ Laparoscopic

■ Open


Platinum Priority – Prostate Cancer

Editorial by XXX on pp. x-y of this issue

A Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22 393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients

Prasanna Sooriakumaran^{a,b,*}, Abhishek Srivastava^c, Shahrokh F. Shariat^{d,e}, Phillip D. Stricker^f, Thomas Ahlering^g, Christopher G. Eden^h, Peter N. Wiklund^b, Rafael Sanchez-Salasⁱ, Alexandre Mottrie^j, David Lee^k, David E. Neal^{l,m}, Reza Ghavamian^c, Peter Nyiradyⁿ, Andreas Nilsson^b, Stefan Carlsson^b, Evangelos Xylinas^d, Wolfgang Loidl^o, Christian Seitz^e, Paul Schramek^p, Claus Roehrborn^q, Xavier Cathelineauⁱ, Douglas Skarecky^g, Greg Shaw^m, Anne Warren^r, Warick J. Delprado^f, Anne-Marie Haynes^f, Ewout Steyerberg^s, Monique J. Roobol^s, Ashutosh K. Tewari^d

^aSurgical Intervention Trials Unit, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; ^bDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; ^cDepartment of Urology, Montefiore Medical Center, New York, NY, USA; ^dDepartment of Urology, Weill Cornell Medical College–New York Presbyterian Hospital, New York, NY, USA; ^eDepartment of Urology, Medical University of Vienna, Vienna, Austria; ^fProstate Cancer Centre, St. Vincent's Clinic, Sydney, Australia; ^gDepartment of Urology, University of California–Irvine School of Medicine, Irvine, CA, USA; ^hDepartment of Urology, Royal Surrey County Hospital, Guildford, UK; ⁱDepartment of Urology, L'Institut Mutualiste Montsouris, Paris, France; ^jDepartment of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ^kDepartment of Urology, University of Pennsylvania, Philadelphia, PA, USA; ^lDepartment of Uro-oncology, University of Cambridge, Cambridge, UK; ^mUro-oncology Research Group, Cancer Research UK, Cambridge Research Institute, Cambridge, UK; ⁿDepartment of Urology, Semmelweis University, Budapest, Hungary; ^oDepartment of Urology, St. Vincent's Hospital, Linz, Austria; ^pDepartment of Urology, Saint John of God Hospital, Vienna, Austria; ^qDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; ^rDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; ^sDepartment of Public Health, Erasmus MC–University Medical Center Rotterdam, Rotterdam, The Netherlands




SM+

Nelson J, AUA Crossfire, 2014,

Tewari Systematic Review Included Series

Open Radical Prostatectomy Series



Robotic Radical Prostatectomy Series

Comparison is hopelessly flawed: Different era, different cancers

Prostate Cancer

Satisfaction and Regret after Open Retropubic or Robot-Assisted Laparoscopic Radical Prostatectomy

Florian R. Schroeck, Tracey L. Krupski, Leon Sun, David M. Albala, Marva M. Price, Thomas

Duke Prostat

Abstract

Background: To counsel patients adequately, it is important to understand the variables influencing satisfaction and regret following prostatectomy.

Objective: To identify independent predictors for satisfaction and regret after radical prostatectomy.

Design, setting, and participants: Patients who had undergone retropubic radical prostatectomy (RRP) or robot-assisted laparoscopic radical prostatectomy (RALP) between 2000 and 2007 were mailed cross-sectional surveys composed of sociodemographic

Patients who underwent RALP were more likely to be regretful and dissatisfied, possibly because of higher expectation of an “innovative” procedure. We suggest that urologists carefully portray the risks and benefits of new technologies during preoperative counseling to minimize regret and maximize satisfaction.

95% CI, 0.57–0.91) and normal domain scores (OR, 0.87; 95% CI, 0.45–0.98), and years since surgery (OR, 1.63; 95% CI, 1.13–2.36) were again predictive ($p \leq 0.041$). African American race (OR, 3.58; 95% CI, 1.52–8.43) and lower bowel domain scores (OR, 0.73; 95% CI, 0.55–0.97) were also independently associated with regret ($p \leq 0.028$).

Conclusions: Sociodemographic variables and quality of life were important variables associated with satisfaction and regret. Patients who underwent RALP were more likely to be regretful and dissatisfied, possibly because of higher expectation of an “innovative” procedure. We suggest that urologists carefully portray the risks and benefits of new technologies during preoperative counseling to minimize regret and maximize satisfaction.

© 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PHASE 3 STUDY

Open versus RALRP



Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study

John WYaxley, Geoffrey D Coughlin, Suzanne K Chambers, Stefano Occhipinti, Hema Samaratunga, Leah Zajdlewicz, Nigel Dungleison, Rob Carter, Scott Williams, Diane J Payton, Joanna Perry-Keene, Martin F Lavin, Robert A Gardiner

n= 326

	Range	Baseline			6 weeks		
		Radical retropubic prostatectomy (n=152)	Robot-assisted laparoscopic prostatectomy (n=153)	p value	Radical retropubic prostatectomy (n=136)	Robot-assisted laparoscopic prostatectomy (n=131)	p value

Primary



Urinary function		Urinary function					
EPIC—urinary domain	0–100	88.79 (86.74–90.85)	88.50 (86.59–90.40)	0.83	74.50 (72.77–77.17)	71.10 (68.22–73.95)	0.09
Sexual function		Sexual function					
EPIC—sexual domain	0–100	59.80 (55.66–63.92)	63.05 (59.32–66.78)	0.25	30.70 (27.18–34.21)	32.70 (28.67–36.79)	0.45
Domain-specific QoL— IIEF total		QoL					
	0–75	43.96 (40.35–47.58)	46.65 (43.07–50.23)	0.30	23.75 (21.03–26.47)	25.63 (22.35–28.92)	0.38

GLEASON 6 - ORRP

Biochemical recurrence

Lepor's series

Nelson's series



PSA Failure Rate

5 years: 1.6%

7 years: 3.4%

10 years: 4.7%

PSA Failure Rate

5 years: 1.3%

7 years: 2.8%

10 years: 3.6%

RALRP X ORRP

Biochemical recurrence 5 years

GLEASON 6

RALRP

- Menon 12.5%
- Suardi 10%
- Karolinska 6%

ORRP

- Lepor 1,6%
- Nelson 1.3%





Conclusions

- RALRP did not improve short term outcomes
-
- ORRP is really a valid option
- Surgeon expertise is key to decision making (more important than the technique)
- Long term follow-up need to assess oncologic outcomes
- RALRP will show better results from now on
 - Reference centers and surgeons moved to robotics


The anterior bladder neck incised with the endopelvic fascia and the dorsal venous complex preserved




The posterior bladder neck is incised




After the Denonvilliers' fascia is incised, the posterior plane of dissection is developed according the planned NS strategy



Dissection of the left neurovascular bundles before ligation of the prostatic pedicle




The dissected prostatic apex and the urethra being incised




Final appearance after removal of the prostate



Vesico-urethral anastomosis (modified van Velthoven continuous suture)



The endopelvic fascia and periprostatic collar are reconstructed with a continuous suture





THANK YOU